Text Size
Trial record 5 of 10 for:    "Autoimmune hepatitis"
Previous Study | Return to List | Next Study

Budesonide 3x3mg/d Versus Prednisone in Active Autoimmune Hepatitis

This study has been completed.
Sponsor:
Information provided by:
Dr. Falk Pharma GmbH
ClinicalTrials.gov Identifier:
NCT00838214
First received: February 5, 2009
Last updated: NA
Last verified: February 2009
History: No changes posted
  Purpose

This is a multicentre, multinational clinical study. It comprised two consecutive segments (A and B). Segment A was designed as a randomized, double-blind, double-dummy, active-controlled, two-arm parallel-group study. The patients received either budesonide or prednisone for 6 months. During segment B all patients received budesonide as an open treatment for additional 6 months.

In this confirmatory study the proportion of patients with complete response was compared between the two treatment groups. Complete response was defined as biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of segment A and lack of steroid specific side effects throughout segment A.


Condition Intervention Phase
Autoimmune Hepatitis
 Drug: budesonide
Drug: prednisone
 Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Efficacy and Safety of Budesonide Capsules (3x3mg/d)Versus Prednisone in Patients With a Diagnose of Active Autoimmune Hepatitis. A Double-Blind, Randomized, Active-Controlled, Multicentre Study

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Dr. Falk Pharma GmbH:

Primary Outcome Measures:
  • Biochemical remission (=serum levels of ASAT and ALAT within normal ranges) at the individual last visit of Segment A and lack of steroid specific side effects [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • incidence of biochemical remission [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Enrollment: 208
Study Start Date: March 2001
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: budesonide
3mg capsules 3x/day for 6 months
 Drug: budesonide
3mg capsule, 3x per day for 6 months
Active Comparator: prednisone
5mg tablet, 40mg starting dose titrated to 10mg over 3 months
 Drug: prednisone
5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months

  Eligibility

Ages Eligible for Study:   10 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • age 10 to 70 years
  • Diagnosis of acute AIH according to Alvarez score
  • normal range of TPMT activity
  • normal ACTH test
  • negative pregnancy test at screening for females of childbearing potential
  • written informed consent

Exclusion Criteria:

  • presence of Hepatitis A, B, C, E or G virus infection
  • liver cirrhosis or clinical signs of portal hypertension
  • PBC
  • PSC
  • history of hypersensitivity to the study medication
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00838214

Locations
Germany
Medical School Hannover
Hannover, Niedersachsen, Germany, D-30625
Sponsors and Collaborators
Dr. Falk Pharma GmbH
Investigators
Principal Investigator: Michael M Manns, Professor University Hospital
  More Information

No publications provided

Responsible Party: Markus Proels, Dr. Falk Pharma, Germany
ClinicalTrials.gov Identifier: NCT00838214     History of Changes
Other Study ID Numbers: BUC-38/AIH
Study First Received: February 5, 2009
Last Updated: February 5, 2009
Health Authority: Germany: Federal Institute for Drugs and Medical Devices
Poland: Ministry of Health
Israel: Ministry of Health

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis, Autoimmune
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepatitis, Chronic
Autoimmune Diseases
Immune System Diseases
Prednisone
Budesonide
 Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Pharmacologic Actions
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Therapeutic Uses
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Anti-Asthmatic Agents
Respiratory System Agents

ClinicalTrials.gov processed this record on May 21, 2013